|
US723288A
(en)
|
1901-10-26 |
1903-03-24 |
Harry South Lewis |
Cipher-key for cryptographic codes.
|
|
WO1988007089A1
(en)
|
1987-03-18 |
1988-09-22 |
Medical Research Council |
Altered antibodies
|
|
WO1989006692A1
(en)
|
1988-01-12 |
1989-07-27 |
Genentech, Inc. |
Method of treating tumor cells by inhibiting growth factor receptor function
|
|
EP1400536A1
(en)
|
1991-06-14 |
2004-03-24 |
Genentech Inc. |
Method for making humanized antibodies
|
|
WO1994004679A1
(en)
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Method for making humanized antibodies
|
|
US6800738B1
(en)
|
1991-06-14 |
2004-10-05 |
Genentech, Inc. |
Method for making humanized antibodies
|
|
US5874540A
(en)
|
1994-10-05 |
1999-02-23 |
Immunomedics, Inc. |
CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
|
|
PT1308456E
(pt)
|
1998-05-06 |
2007-12-03 |
Genentech Inc |
Purificação de anticorpos por cromatografia de permuta iónica
|
|
CA2370245A1
(en)
|
1999-05-14 |
2000-11-23 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Enzyme-activated anti-tumor prodrug compounds
|
|
US6949245B1
(en)
|
1999-06-25 |
2005-09-27 |
Genentech, Inc. |
Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
|
|
CA2399940A1
(en)
|
2000-04-13 |
2001-10-25 |
The Rockefeller University |
Enhancement of antibody-mediated immune responses
|
|
EP1238678A1
(en)
|
2001-03-08 |
2002-09-11 |
Bayer Aktiengesellschaft |
Enzyme-activated cytostatic conjugates with integrin ligands
|
|
WO2003074566A2
(en)
|
2002-03-01 |
2003-09-12 |
Immunomedics, Inc. |
Rs7 antibodies
|
|
WO2005086875A2
(en)
|
2004-03-11 |
2005-09-22 |
City Of Hope |
A humanized anti-cea t84.66 antibody and uses thereof
|
|
KR101270829B1
(ko)
|
2004-09-23 |
2013-06-07 |
제넨테크, 인크. |
시스테인 유전자조작 항체 및 접합체
|
|
WO2006073921A2
(en)
|
2004-12-30 |
2006-07-13 |
The Rockefeller University |
Compositions and methods for enhanced dendritic cell maturation and function
|
|
US20080286819A1
(en)
|
2005-11-07 |
2008-11-20 |
Ravetch Jeffrey V |
Reagents, Methods and Systems for Selecting a Cytotoxic Antibody or Variant Thereof
|
|
LT1976880T
(lt)
|
2005-12-21 |
2016-10-10 |
Amgen Research (Munich) Gmbh |
Farmacinės kompozicijos, pasižyminčios atsparumu tirpiam cea
|
|
US7420040B2
(en)
|
2006-02-24 |
2008-09-02 |
Arius Research Inc. |
Cytotoxicity mediation of cells evidencing surface expression of TROP-2
|
|
US20080131428A1
(en)
|
2006-02-24 |
2008-06-05 |
Arius Research, Inc. |
Cytotoxicity mediation of cells evidencing surface expression of TROP-2
|
|
EP2144628B1
(en)
|
2007-05-08 |
2012-10-17 |
Genentech, Inc. |
Cysteine engineered anti-muc16 antibodies and antibody drug conjugates
|
|
MX2010003718A
(es)
|
2007-10-19 |
2010-04-21 |
Genentech Inc |
Anticuerpos anti-tenb2 producidos por ingenieria de cisteina y conjugados de farmaco y anticuerpo.
|
|
EP3912643B8
(en)
|
2009-02-13 |
2023-08-23 |
Immunomedics, Inc. |
Immunoconjugates with an intracellularly-cleavable linkage
|
|
ES2978177T3
(es)
|
2009-12-02 |
2024-09-06 |
Immunomedics Inc |
Combinación de radio inmunoterapia y conjugados anticuerpo-fármaco para mejorar la terapia contra el cáncer
|
|
HUE025678T2
(en)
|
2010-02-04 |
2016-04-28 |
Toray Industries |
A pharmaceutical composition for the treatment and / or prevention of cancer
|
|
MX369106B
(es)
|
2010-05-17 |
2019-10-29 |
Chiome Bioscience Inc |
Anticuerpo anti trop-2 humano que tiene actividad anti-tumoral in vivo.
|
|
JPWO2011155579A1
(ja)
|
2010-06-10 |
2013-08-15 |
北海道公立大学法人 札幌医科大学 |
抗Ｔｒｏｐ−２抗体
|
|
JP5889912B2
(ja)
|
2010-11-17 |
2016-03-22 |
ジェネンテック， インコーポレイテッド |
アラニニルメイタンシノール抗体コンジュゲート
|
|
RS56793B1
(sr)
|
2011-03-02 |
2018-04-30 |
Roche Glycart Ag |
Cea antitela
|
|
RU2595400C2
(ru)
|
2011-08-04 |
2016-08-27 |
Торэй Индастриз, Инк. |
Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли
|
|
PT2740794T
(pt)
|
2011-08-04 |
2018-06-14 |
Toray Industries |
Composição farmacêutica para o tratamento e/ou profilaxia de cancro
|
|
US9181348B2
(en)
|
2011-08-04 |
2015-11-10 |
Toray Industries, Inc. |
Pharmaceutical composition for treatment and/or prophylaxis of cancer
|
|
PT2740793T
(pt)
|
2011-08-04 |
2018-02-23 |
Toray Industries |
Composição de fármacos para o tratamento e/ou a prevenção de cancro
|
|
AU2012335205A1
(en)
|
2011-11-11 |
2014-05-29 |
Rinat Neuroscience Corp. |
Antibodies specific for Trop-2 and their uses
|
|
US9427464B2
(en)
|
2011-11-22 |
2016-08-30 |
Chiome Bioscience Inc. |
Anti-human TROP-2 antibody having an antitumor activity in vivo
|
|
US9260513B2
(en)
|
2012-02-21 |
2016-02-16 |
Toray Industries, Inc. |
Pharmaceutical composition for treatment and/or prevention of cancer
|
|
HUE044611T2
(hu)
|
2012-02-21 |
2019-11-28 |
Toray Industries |
Gyógyászati készítmény rák kezelésére
|
|
BR112014021103A2
(pt)
|
2012-02-21 |
2019-10-15 |
Toray Industries, Inc |
Anticorpo, composição farmacêutica, droga de combinação, dna, método de tratamento e uso de anticorpo
|
|
PT2818483T
(pt)
|
2012-02-21 |
2017-10-09 |
Toray Industries |
Composição medicinal para tratamento e/ou prevenção de cancro
|
|
RU2646466C2
(ru)
|
2012-07-19 |
2018-03-05 |
Торэй Индастриз, Инк. |
Метод детекции рака
|
|
PL2876447T3
(pl)
|
2012-07-19 |
2020-05-18 |
Toray Industries, Inc. |
Sposób wykrywania nowotworu
|
|
US9382329B2
(en)
|
2012-08-14 |
2016-07-05 |
Ibc Pharmaceuticals, Inc. |
Disease therapy by inducing immune response to Trop-2 expressing cells
|
|
HUE033369T2
(en)
|
2012-11-20 |
2017-11-28 |
Sanofi Sa |
Anti-ceacam5 antibodies and uses thereof
|
|
ES2704909T3
(es)
|
2013-08-09 |
2019-03-20 |
Toray Industries |
Composición farmacéutica para el tratamiento y/o la prevención del cáncer
|
|
LT3424955T
(lt)
|
2013-12-25 |
2025-06-25 |
Daiichi Sankyo Company, Limited |
Anti-trop2 antikūno ir vaisto konjugato gamybos būdas
|
|
US9676863B2
(en)
|
2014-02-10 |
2017-06-13 |
Merck Patent Gmbh |
Targeted TGFβ inhibitors
|
|
TW201623265A
(zh)
|
2014-05-09 |
2016-07-01 |
奇尼塔公司 |
抗病毒化合物、醫藥組合物及其使用方法
|
|
MY189836A
(en)
|
2014-11-21 |
2022-03-11 |
Bristol Myers Squibb Co |
Antibodies against cd73 and uses thereof
|
|
WO2016172427A1
(en)
|
2015-04-22 |
2016-10-27 |
Immunomedics, Inc. |
Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells
|
|
WO2017156152A1
(en)
|
2016-03-08 |
2017-09-14 |
Bioxcel Corporation |
Immunomodulation therapies for cancer
|
|
KR20240005247A
(ko)
|
2016-10-28 |
2024-01-11 |
도레이 카부시키가이샤 |
암의 치료 및/또는 예방용 의약 조성물
|
|
CN111194214A
(zh)
*
|
2017-10-05 |
2020-05-22 |
葛兰素史密斯克莱知识产权发展有限公司 |
施用sting激动剂的方法
|
|
WO2019084060A1
(en)
*
|
2017-10-24 |
2019-05-02 |
Silverback Therapeutics, Inc. |
CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS
|
|
US10793557B2
(en)
|
2018-04-03 |
2020-10-06 |
Merck Sharp & Dohme Corp. |
Sting agonist compounds
|
|
WO2019222676A1
(en)
*
|
2018-05-17 |
2019-11-21 |
Bolt Biotherapeutics, Inc. |
Immunoconjugates
|
|
CN113543808A
(zh)
|
2019-01-04 |
2021-10-22 |
特瑞奥制药公司 |
多特异性蛋白质分子及其用途
|
|
AU2020291014B2
(en)
*
|
2019-06-13 |
2025-06-05 |
Bolt Biotherapeutics, Inc. |
Aminobenzazepine compounds, immunoconjugates, and uses thereof
|
|
CA3148694A1
(en)
*
|
2019-09-03 |
2021-03-11 |
Romas Kudirka |
Aminoquinoline compounds, immunoconjugates, and uses thereof
|
|
JP2022549510A
(ja)
*
|
2019-09-30 |
2022-11-25 |
ボルト バイオセラピューティクス、インコーポレーテッド |
アミド結合したアミノベンズアゼピン免疫複合体、及びその使用
|
|
CA3155077A1
(en)
*
|
2019-10-25 |
2021-04-29 |
Romas Kudirka |
Thienoazepine immunoconjugates, and uses thereof
|